Christopher D. Roberts's most recent trade in Black Diamond Therapeutics Inc was a trade of 2,500 Common Stock done at an average price of $26.6 . Disclosure was reported to the exchange on May 3, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.64 per share. | 03 May 2021 | 2,500 | 3,200 (0%) | 0% | 26.6 | 66,602 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2021 | 2,500 | 163,609 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 May 2021 | 2,500 | 5,700 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.54 per share. | 05 Apr 2021 | 2,500 | 3,200 (0%) | 0% | 25.5 | 63,848 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 2,500 | 166,109 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 05 Apr 2021 | 2,500 | 5,700 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 Mar 2021 | 2,500 | 5,700 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2021 | 2,500 | 168,609 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.85 per share. | 03 Mar 2021 | 1,616 | 4,084 (0%) | 0% | 25.9 | 41,778 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.57 per share. | 03 Mar 2021 | 884 | 3,200 (0%) | 0% | 26.6 | 23,484 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.35 per share. | 03 Feb 2021 | 2,500 | 3,200 (0%) | 0% | 25.4 | 63,375 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 2,500 | 171,109 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 Feb 2021 | 2,500 | 5,700 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 2,500 | 173,609 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 04 Jan 2021 | 2,500 | 5,700 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.31 per share. | 04 Jan 2021 | 1,963 | 3,737 (0%) | 0% | 31.3 | 61,460 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.78 per share. | 04 Jan 2021 | 537 | 3,200 (0%) | 0% | 31.8 | 17,065 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 15 Dec 2020 | 3,200 | 3,200 (0%) | 0% | 10.9 | 34,752 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 3,200 | 176,109 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.42 per share. | 03 Dec 2020 | 2,500 | 0 (0%) | 0% | 32.4 | 81,055 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2020 | 2,500 | 179,309 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 Dec 2020 | 2,500 | 2,500 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 5,000 | 181,809 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 11 Nov 2020 | 5,000 | 0 (0%) | 0% | 34.9 | 174,500 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 11 Nov 2020 | 5,000 | 5,000 (0%) | 0% | 10.9 | 54,300 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.95 per share. | 03 Nov 2020 | 2,500 | 0 (0%) | 0% | 31.9 | 79,873 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2020 | 2,500 | 186,809 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 Nov 2020 | 2,500 | 2,500 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 2,500 | 189,309 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 05 Oct 2020 | 2,500 | 2,500 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.20 per share. | 05 Oct 2020 | 2,273 | 227 (0%) | 0% | 31.2 | 70,927 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.99 per share. | 05 Oct 2020 | 227 | 0 (0%) | 0% | 32.0 | 7,261 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2020 | 2,500 | 191,809 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.86 per share. | 03 Sep 2020 | 2,500 | 2,500 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.63 per share. | 03 Sep 2020 | 2,358 | 0 (0%) | 0% | 29.6 | 69,877 | Common Stock |
| Black Diamond Therapeutics... | Christopher D. Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.95 per share. | 03 Sep 2020 | 142 | 2,358 (0%) | 0% | 29.0 | 4,111 | Common Stock |